Regulatory Approvals

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

By

Regulatory Approvals — FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease  Novartis

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 7, 2026.

By

Related Post

Regulatory Approvals

FDA Approves RP1 Plus Nivolumab for Advanced Melanoma

Regulatory Approvals

FDA approves Orzeyful for narcolepsy type 1 in adults

Regulatory Approvals

FDA Approves First mRNA Flu Vaccine – respiratory

Financial News For All

Labor

When the Layoffs Come: What North Carolina Employers Need to Know About the WARN Act

Labor

Dallas city manager signals possible layoffs for city employees ahead of next month’s budget vote – NBC 5 Dallas

Regulatory Approvals

FDA Approves RP1 Plus Nivolumab for Advanced Melanoma

Regulatory Approvals

FDA approves first mRNA-based flu vaccine